ATAI - atai Life Sciences increases its ownership position in COMPASS Pathways

atai Life Sciences (NASDAQ:ATAI) increased its ownership interest in COMPASS Pathways from 19.4% to 20.8% indicating the potential of COMP360 in mental health care, post the recent COMP360 data in treatment-resistant depression. Over 300M people worldwide live with depression and, of these, a third struggle with treatment-resistant depression (TRD) that cannot be managed by currently available options. COMPASS's Phase 2b trial of COMP360 psilocybin in TRD is the largest and most robust trial ever to be conducted with psilocybin; Phase 3 study of psilocybin in TRD is anticipated to launch in 2022. Furthermore, COMPASS is exploring the potential of COMP360 towards several further potential indications including type 2 bipolar disorder depression, anorexia nervosa, body dysmorphia, suicidal ideation and autism. "By developing COMP360 and other novel 5-HT2a agonists, COMPASS is highly complementary to our diversified platform and fully aligns with our vision to heal mental health disorders," Founder and Chairman Christian Angermayer commented.

For further details see:

atai Life Sciences increases its ownership position in COMPASS Pathways